FIBROGEN INC - COMMON

0,2639

13-июня-25 13:45:00

15 мин. задержка

Акции

-0,0446

-14,46%

Сегодняшний диапазон

0,2423 - 0,2885

ISIN

N/A

Источник

NASDAQ

FibroGen Receives Rare Pediatric Disease Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy

15 апр 2021 04:00:00 Источник Nasdaq GlobeNewswire
FibroGen Receives Fast Track Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy

12 апр 2021 04:00:01 Источник Nasdaq GlobeNewswire
FibroGen Announces FDA Advisory Committee to Review Roxadustat New Drug Application Tentatively Scheduled for July 15, 2021

06 апр 2021 16:50:31 Источник Nasdaq GlobeNewswire
FibroGen Provides Additional Information on Roxadustat

06 апр 2021 13:01:00 Источник Nasdaq GlobeNewswire
FibroGen Initiates LELANTOS-2 – Second Phase 3 Clinical Study of Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy

16 мар 2021 04:00:00 Источник Nasdaq GlobeNewswire
FibroGen Reports Fourth Quarter and Full Year 2020 Financial Results

01 мар 2021 13:01:00 Источник Nasdaq GlobeNewswire
FibroGen Provides Regulatory Update on Roxadustat

01 мар 2021 13:01:00 Источник Nasdaq GlobeNewswire
FibroGen to Report Fourth Quarter and Full Year 2020 Financial Results

18 фев 2021 04:00:01 Источник Nasdaq GlobeNewswire
FibroGen to Present at Upcoming Investor Conferences

12 фев 2021 04:00:00 Источник Nasdaq GlobeNewswire

<<
<
2
3
4
5
6
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.